Table 2. Distribution of patient and... | American Society of Hematology

Table 2.

Distribution of patient and disease characteristics according to treatment group

Characteristics	CHOP + G-CSF	CNOP + G-CSF	CHOP	CNOP	CHF class I/II
Characteristics	CHOP + G-CSF	CNOP + G-CSF	CHOP	CNOP	CNOP + G-CSF	CNOP
n	101	103	104	100	22	25
Age
Median, y	71	70	72	71	75	72
Older than 70 y, %	62	51	64	59	73	60
Sex, %
Male	49	49	54	53	64	64
Female	51	51	46	47	36	36
Clinical stage, %
I	0	1	0	0	0	0
II	34	31	38	35	32	28
III	31	26	22	23	32	36
IV	35	42	40	42	36	36
Bulky disease, %	56	53	59	50	45	48
Bone marrow involvement, %	15	17	13	13	14	20
LDH level above normal, %	62	68	63	63	62	68
Performance status (WHO), %
0-1	69	65	76	60	55	68
2-3	31	35	24	40	45	32
Extranodal sites (>1), %	10	14	13	13	18	20
IPI (clinical stage, LDH, and performance status), %
0	20	15	12	16	9	8
1	24	26	40	24	29	28
2	36	33	36	36	33	48
3	20	26	12	24	29	16
Histopathology^*
Kiel classification, %
Centroblastic	61	63	69	69	77	56
Immunoblastic	1	4	3	4	0	12
Anaplastic LC	2	0	0	2	0	0
Lymphoblastic	2	0	0	3	0	0
Pleomorphic T	10	6	8	2	9	0
Other high-grade	14	20	12	10	14	12
Other (cytology, low-grade, Hodgkin lymphoma)	10	7	8	10	0	20
REAL classification, %
Diffuse large B cell	62	67	72	73	77	68
Anaplastic large cell	2	0	0	2	0	0
Lymphoblastic (B and T)	2	0	0	3	0	0
Peripheral T cell	10	6	8	2	9	0
Other high-grade	14	20	12	10	14	12
(B and T)
Other (cytology, low-grade, Hodgkin lymphoma)	10	7	8	10	0	20

Characteristics	CHOP + G-CSF	CNOP + G-CSF	CHOP	CNOP	CHF class I/II
Characteristics	CHOP + G-CSF	CNOP + G-CSF	CHOP	CNOP	CNOP + G-CSF	CNOP
n	101	103	104	100	22	25
Age
Median, y	71	70	72	71	75	72
Older than 70 y, %	62	51	64	59	73	60
Sex, %
Male	49	49	54	53	64	64
Female	51	51	46	47	36	36
Clinical stage, %
I	0	1	0	0	0	0
II	34	31	38	35	32	28
III	31	26	22	23	32	36
IV	35	42	40	42	36	36
Bulky disease, %	56	53	59	50	45	48
Bone marrow involvement, %	15	17	13	13	14	20
LDH level above normal, %	62	68	63	63	62	68
Performance status (WHO), %
0-1	69	65	76	60	55	68
2-3	31	35	24	40	45	32
Extranodal sites (>1), %	10	14	13	13	18	20
IPI (clinical stage, LDH, and performance status), %
0	20	15	12	16	9	8
1	24	26	40	24	29	28
2	36	33	36	36	33	48
3	20	26	12	24	29	16
Histopathology^*
Kiel classification, %
Centroblastic	61	63	69	69	77	56
Immunoblastic	1	4	3	4	0	12
Anaplastic LC	2	0	0	2	0	0
Lymphoblastic	2	0	0	3	0	0
Pleomorphic T	10	6	8	2	9	0
Other high-grade	14	20	12	10	14	12
Other (cytology, low-grade, Hodgkin lymphoma)	10	7	8	10	0	20
REAL classification, %
Diffuse large B cell	62	67	72	73	77	68
Anaplastic large cell	2	0	0	2	0	0
Lymphoblastic (B and T)	2	0	0	3	0	0
Peripheral T cell	10	6	8	2	9	0
Other high-grade	14	20	12	10	14	12
(B and T)
Other (cytology, low-grade, Hodgkin lymphoma)	10	7	8	10	0	20

LDH indicates lactate dehydrogenase; IPI, International Prognostic Index; LC, large cell.

According to central pathology review.